Concurrent Weekly Cisplatin Versus Triweekly Cisplatin with Radiotherapy in the Treatment of Cervical Cancer: A Metaanalysis Result

Aims: To evaluate the adverse effect and survival outcome of weekly and triweekly cisplatin with radiotherapyin treatment of cervical cancer.
Methods: After an extensive literature search between 1995-2011,we analyzed7 studies to compare weekly cisplatin and triweekly cisplatin combined radiotherapy.
Results: Our analysisestablished that weekly cisplatin has a lower risk of hematologic toxicity than triweekly cisplatin with concurrentradiotherapy in the treatment of cervical cancer. However, there were no differences in progression free survivaland overall survival between weekly cisplatin and triweekly cisplatin (p>0.05).
Conclusions: Weekly cisplatincombined with concurrent radiation has lower risk in hematologic toxicity than triweekly cisplatin, but does notimprove survival. Triweekly cisplatin treatment has longer intervals and is therefore more convenient. Cliniciansand patients can choose either weekly cisplatin or triweekly cisplatin combined radiotherapy for cervical cancer.